Some content of this application is unavailable at the moment.
If this situation persist, please contact us atFeedback&Contact
1. (WO2019008441) COMPOUNDS COMPRISING CLEAVABLE LINKER AND USES THEREOF
Latest bibliographic data on file with the International Bureau    Submit observation

Pub. No.: WO/2019/008441 International Application No.: PCT/IB2018/000847
Publication Date: 10.01.2019 International Filing Date: 03.07.2018
IPC:
C07H 15/203 (2006.01) ,C07K 16/40 (2006.01) ,C07C 305/24 (2006.01) ,C01B 33/00 (2006.01) ,A61K 47/22 (2006.01) ,A61K 47/68 (2017.01) ,A61P 35/00 (2006.01)
C CHEMISTRY; METALLURGY
07
ORGANIC CHEMISTRY
H
SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
15
Compounds containing hydrocarbon or substituted hydrocarbon radicals directly attached to hetero atoms of saccharide radicals
20
Carbocyclic rings
203
Monocyclic carbocyclic rings other than cyclohexane rings; Bicyclic carbocyclic ring systems
C CHEMISTRY; METALLURGY
07
ORGANIC CHEMISTRY
K
PEPTIDES
16
Immunoglobulins, e.g. monoclonal or polyclonal antibodies
40
against enzymes
C CHEMISTRY; METALLURGY
07
ORGANIC CHEMISTRY
C
ACYCLIC OR CARBOCYCLIC COMPOUNDS
305
Esters of sulfuric acids
22
having oxygen atoms of sulfate groups bound to carbon atoms of six-membered aromatic rings
24
of non-condensed six-membered aromatic rings
C CHEMISTRY; METALLURGY
01
INORGANIC CHEMISTRY
B
NON-METALLIC ELEMENTS; COMPOUNDS THEREOF
33
Silicon; Compounds thereof
A HUMAN NECESSITIES
61
MEDICAL OR VETERINARY SCIENCE; HYGIENE
K
PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
47
Medicinal preparations characterised by the non-active ingredients used, e.g. carriers, inert additives
06
Organic compounds
22
Heterocyclic compounds
[IPC code unknown for A61K 47/68]
A HUMAN NECESSITIES
61
MEDICAL OR VETERINARY SCIENCE; HYGIENE
P
SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
35
Antineoplastic agents
Applicants:
PARK, Taekyo; KR
WOO, Sung Ho; KR
KIM, Sunyoung; KR
PARK, Suho; KR
CHO, Jongun; KR
JUNG, Doohwan; KR
SEO, Donghoon; KR
LEE, Jaeho; KR
LEE, Sangkwang; KR
YUN, Sanghyeon; KR
LEE, Hyang Sook; KR
PARK, Okku; KR
SEO, Beomseok; KR
INTOCELL, INC. [KR/KR]; 8-26 Munpyeongseo-ro Daedeok-gu Daejeon 306-220, KR
Inventors:
PARK, Taekyo; KR
WOO, Sung Ho; KR
KIM, Sunyoung; KR
PARK, Suho; KR
CHO, Jongun; KR
JUNG, Doohwan; KR
SEO, Donghoon; KR
LEE, Jaeho; KR
LEE, Sangkwang; KR
YUN, Sanghyeon; KR
LEE, Hyang Sook; KR
PARK, Okku; KR
SEO, Beomseok; KR
Priority Data:
10-2017-008480504.07.2017KR
62/597,22611.12.2017US
Title (EN) COMPOUNDS COMPRISING CLEAVABLE LINKER AND USES THEREOF
(FR) COMPOSÉS COMPRENANT UN LIEUR CLIVABLE ET LEURS UTILISATIONS
Abstract:
(EN) Provided are a compound including a cleavable linker, a use thereof, and an intermediate compound for preparing the same, and more particularly, the compound including a cleavable linker of the present invention may include an active agent (for example, a drug, a toxin, a ligand, a probe for detection, etc.) having a specific function or activity, a SO2 functional group which is capable of selectively releasing the active agent, and a functional group which triggers a chemical reaction, a physicochemical reaction and/or a biological reaction by external stimulation, and may further include a ligand (for example, oligopeptide, polypeptide, antibody, etc.) having binding specificity for a desired target receptor.
(FR) L'invention concerne un composé comprenant un lieur clivable, son utilisation, et un composé intermédiaire pour sa préparation, et plus particulièrement, le composé comprenant un lieur clivable de la présente invention peut comprendre un agent actif (par exemple, un médicament, une toxine, un ligand, une sonde de détection, etc.) Le composé comprenant un lieur clivable selon la présente invention a une fonction ou une activité spécifique, un groupe fonctionnel SO2 capable de libérer de manière sélective l'agent actif, et un groupe fonctionnel qui déclenche une réaction chimique, une réaction physico-chimique et/ou une réaction biologique par stimulation externe, et peut en outre comprendre un ligand (par exemple, un oligopeptide, un polypeptide, un anticorps, etc.) Le composé de la présente invention possède également une spécificité de liaison pour un récepteur cible souhaité.
Designated States: AE, AG, AL, AM, AO, AT, AU, AZ, BA, BB, BG, BH, BN, BR, BW, BY, BZ, CA, CH, CL, CN, CO, CR, CU, CZ, DE, DJ, DK, DM, DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, HR, HU, ID, IL, IN, IR, IS, JO, JP, KE, KG, KH, KN, KP, KR, KW, KZ, LA, LC, LK, LR, LS, LU, LY, MA, MD, ME, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PA, PE, PG, PH, PL, PT, QA, RO, RS, RU, RW, SA, SC, SD, SE, SG, SK, SL, SM, ST, SV, SY, TH, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, ZA, ZM, ZW
African Regional Intellectual Property Organization (ARIPO) (BW, GH, GM, KE, LR, LS, MW, MZ, NA, RW, SD, SL, ST, SZ, TZ, UG, ZM, ZW)
Eurasian Patent Office (AM, AZ, BY, KG, KZ, RU, TJ, TM)
European Patent Office (EPO) (AL, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT, LU, LV, MC, MK, MT, NL, NO, PL, PT, RO, RS, SE, SI, SK, SM, TR)
African Intellectual Property Organization (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, KM, ML, MR, NE, SN, TD, TG)
Publication Language: English (EN)
Filing Language: English (EN)